Q3 FY2026 · ended Feb 28, 2026 · Revenue $0 · Filed Jun 16, 2026
Exousia Bio, Inc. (LMMY) files with the SEC under industry code 8200, Services-Educational Services. In Q3 of fiscal 2026, the quarter ended Feb 28, 2026, it reported revenue of $0 and net income of $0. Free cash flow was $0.
Revenue
$0
Net income
$0
-100.0% vs year-ago quarter
Operating cash flow
$0
Free cash flow
$0
-100.0% vs prior quarter
EPS
$0.00
-100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
52.50M
+575.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Services-Educational Services (SIC 8200)
- Listed as
- LMMY (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- WY
- Headquarters
- St. Petersburg, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1939937
- Former names
- LAMY (until Jan 15, 2026); L A M Y (until Apr 15, 2024)
Other Services-Educational Services companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
Q4 FY2025 May 31, 2025 |
Q3 FY2025 Feb 28, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | $0 | -$237,005 | -$31,814 | — | — |
| Net income | $0 | -$19,083 | -$31,814 | -$29,264 | $61,833 |
| Diluted EPS | $0.00 | $0.00 | $0.00 | -$0.00 | $0.01 |
| Operating cash flow | $0 | $173,126 | $3,500 | -$91,066 | $0 |
| Free cash flow | $0 | $172,456 | — | — | — |
| Total assets | $22.1M | $22.1M | $0 | $0 | $0 |
| Total liabilities | $261,023 | $261,023 | $35,314 | $0 | $0 |
| Stockholders' equity | $21.8M | $21.8M | -$35,314 | $0 | $24,854 |
| Cash and investments | $0 | $0 | $0 | $0 | $1,028 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jun 16, 2026 | Feb 28, 2026 |
| 10-Q | Quarterly report | Mar 17, 2026 | Nov 30, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Officer or director change
|
Nov 17, 2025 | Nov 11, 2025 |
| 10-Q | Quarterly report | Nov 17, 2025 | Aug 31, 2025 |
| 10-K | Annual report | Oct 17, 2025 | May 31, 2025 |
| 10-Q | Quarterly report | Apr 24, 2025 | Feb 28, 2025 |
All 50 Exousia Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.